VIG vs XBI
Vanguard Dividend Appreciation ETF vs SPDR S&P Biotech ETF
- • VIG has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • VIG pays a higher dividend yield (1.47%).
Side-by-side metrics
| Metric | VIG | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.47% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $135.70B | $10.92B |
YTD return | 14.79% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.70 | 1.01 |
P/E ratio | 26.31 | — |
Last price | $251.63 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VIG top holdings
| MSFT | Microsoft Corp | 4.91% |
| AAPL | Apple Inc | 4.89% |
| AVGO | Broadcom Inc | 4.30% |
| LLY | Eli Lilly and Co | 4.10% |
| JPM | JPMorgan Chase & Co | 3.90% |
| XOM | ExxonMobil Holdings Corp | 2.97% |
| JNJ | Johnson & Johnson | 2.83% |
| V | Visa Inc Class A | 2.53% |
| WMT | Walmart Inc | 2.05% |
| ABBV | AbbVie Inc | 2.05% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VIG
VIG (Vanguard Dividend Appreciation ETF) is US companies with a record of growing dividends. Managed by Vanguard, the fund carries $135.7B in assets under management, an expense ratio of 0.04%, a dividend yield of 1.47%. Its largest holding is Microsoft Corp (MSFT), which represents 4.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 3.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.